Aventis/P&G Actonel once-weekly
Executive Summary
Aventis expects to launch once-weekly version of the osteoporosis agent Actonel (risedronate) by mid-May, company tells Deutsche Bank healthcare conference May 8 in Baltimore. Actonel's share of new prescriptions has recovered to a level higher than before Merck launched the once-weekly Fosamax (alendronate) at the end of 2000, company says: Actonel held a 10.69% prescription share as of April...